Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility
- PMID: 15861212
- DOI: 10.1038/modpathol.3800432
Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility
Abstract
Accurate determination of HER-2 status is important in the management of patients with breast cancer, especially in determining their eligibility for trastuzumab therapy. Fluorescence in situ hybridization (FISH) has been regarded as the gold standard method for detecting HER-2 gene amplification. Recently, chromogenic in situ hybridization (CISH), in which HER-2 is detected by a peroxidase reaction and the gene copies are determined by regular bright-field microscopy, has emerged as a potential alternative to FISH. However, this method requires validation before it can be adopted into clinical practice. In this study, we evaluated 80 cases of invasive breast carcinoma by CISH, compared the results with those obtained by FISH, and assessed interobserver reproducibility among three observers. We found that agreement among the three pathologists on the CISH-determined HER-2 status was achieved in 73 cases (91%), all of which had results matching the corresponding FISH results: 54 nonamplified and 19 amplified. Of the 19 amplified cases, 13 were scored unanimously as high-level amplification; six had a minor scoring discrepancy (ie, low-level vs high-level amplification). A major scoring discrepancy (ie, nonamplification vs amplification) was found in the remaining seven cases, three of which were amplified and four of which were nonamplified by FISH. Two of the latter cases had a polysomy of chromosome 17. The cases that caused scoring difficulty were those with an equivocal or borderline signal number against a high background. Overall, there was nearly perfect agreement between the CISH and corresponding FISH results, and interpretation of CISH results were highly reproducible among the three pathologists. We conclude that, in general, HER-2 status can be reliably assessed by CISH. Confirmatory FISH is recommended in cases with equivocal or borderline CISH copy numbers.
Similar articles
-
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.Clin Cancer Res. 2004 Jul 15;10(14):4793-8. doi: 10.1158/1078-0432.CCR-0428-03. Clin Cancer Res. 2004. PMID: 15269154
-
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Ann Pathol. 2011. PMID: 22172120 Review. French.
-
Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.Diagn Cytopathol. 2005 Dec;33(6):376-80. doi: 10.1002/dc.20401. Diagn Cytopathol. 2005. PMID: 16299744
-
Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?Am J Clin Pathol. 2005 Feb;123(2):237-43. Am J Clin Pathol. 2005. PMID: 15842048
-
Emerging technologies for assessing HER2 amplification.Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ. Am J Clin Pathol. 2009. PMID: 19762531 Review.
Cited by
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.Braz J Med Biol Res. 2013 Mar;46(3):207-16. doi: 10.1590/1414-431x20132483. Epub 2013 Mar 19. Braz J Med Biol Res. 2013. PMID: 23558859 Free PMC article. Review.
-
EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study.BMJ Open. 2013 Jan 28;3(1):e002077. doi: 10.1136/bmjopen-2012-002077. BMJ Open. 2013. PMID: 23358562 Free PMC article.
-
Testing for HER2 in Breast Cancer: A Continuing Evolution.Patholog Res Int. 2010 Dec 6;2011:903202. doi: 10.4061/2011/903202. Patholog Res Int. 2010. PMID: 21188214 Free PMC article.
-
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.Patholog Res Int. 2010 Dec 6;2011:674182. doi: 10.4061/2011/674182. Patholog Res Int. 2010. PMID: 21188213 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous